Eye Transplants After Death and Fusogenic Spinal Cord Repair Breakthroughs

Podcast snapshot

In this episode we explore two major transplant frontiers. First, scientists have kept donor retinas alive outside the body for up to 10 hours after death using an eye care box, a step toward potential eye transplants and vision restoration. Second, a fusogenic neurosurgery approach in pigs has shown that severed spinal cords can be coaxed toward connection and functional movement, with electrical stimulation and supportive therapies. The conversation also touches on face transplants, the ethics of head and body transplantation, and how these feats may influence future treatments for spinal injury and blindness.

• Retina viability after death and prospects for eye transplantation
• Spinal cord fusion in animal models using PEG and chitosan
• Head transplantation debates and ethical/regulatory considerations
• Alternative approaches to spinal cord injury repair and future outlook

Overview

The hosts discuss two remarkable steps in transplant surgery. The first is a method to keep human retinas alive after death so that an eye transplant might become feasible in the future. The second is a fusogenic approach to repairing severed spinal cords in pigs, which could someday improve outcomes for spinal injuries and provoke discussions about head or body transplantation. The episode also references a 2023 partial eye and face transplant and contrasts current capabilities with science fiction concepts, clarifying what remains scientifically achievable today.

Eye viability after death and retina transplant prospects

Retinal tissue is the light sensitive layer at the back of the eye that converts light into signals the brain interprets as images. Scientists have developed a device called an eye in care box that allows a donor eye to be perfused with an oxygenated solution via the ophthalmic artery. The system automatically regulates pressure and flow so the retina remains metabolically healthy. In tests, eyes from several donors were perfused, with some retinas showing electrical responses to light while perfused, and others failing when not perfused. The team found that 15 of 36 retinas perfused produced light responses, a sign of retained responsiveness similar to living tissue. This doubles the previous 5 hour window reported in 2022 to up to 10 hours post mortem, creating a window to perform complex transplantation work that would require reconnecting the retina to the optic nerve and then to brain tissue. The retina is particularly delicate because it needs oxygen, and restoring vision after transplantation is not just about keeping the retina alive but also regenerating the optic nerve fibers and reestablishing connections with the visual centers in the brain. The discussion also situates this work in the broader context of eye disease, including age related macular degeneration, and notes that cornea transplants are more established, whereas retina restoration remains challenging.

Eye transplants in context and related cases

The conversation notes that a 2023 partial eye and face transplant provided a living eye on the patient but did not restore vision, underscoring that an intact, functioning retina or optic nerve is central to visual restoration. The team emphasizes that although the retina can be kept alive longer outside the body, achieving a fully functional transplant requires connecting the retina to the optic nerve and the brain, which presents a separate, substantial challenge beyond metabolic support.

Spinal cord fusogens and recovery in animal models

The second major story concerns fusogenic neurosurgery used in pigs to repair severed spinal cords. In this study, anesthetized pigs had the bony arch around the spinal cord removed and the cord ends aligned. They applied a fusogen composed of polyethylene glycol (PEG) and chitosan, a polymer derived from crustacean shells, which is infused at the injury site and accompanied by daily electrical stimulation and anti inflammatory and anti intestinal obstruction drugs. At the start, all treated and control animals exhibited motor and sensory paraplegia. Remarkably, by day 7, treated animals showed movement in the hind limbs, and by day 60 all treated pigs could walk, albeit with some unsteadiness. This outcome suggests that electrical conduction across the wound pathway was being established in the treated group and that recovery depends on guiding axons back to their natural targets rather than random regrowth alone. The study is framed as part of a broader line of inquiry into spinal cord repair, with earlier work in mice and broader questions about how to translate these results to humans.

Context, debate and future directions

The episode situates fusogenic approaches within a broader debate about the direction of spinal injury treatments and human head or body transplantation. It references Sergio Canavero, a controversial neurosurgeon who has discussed head transplantation as a future possibility and notes that the Russian context provides a comparatively permissive regulatory environment for this kind of work. The discussion acknowledges that larger animal studies and careful human trials would be required to assess safety, efficacy, and ethical implications. It also contrasts fusogens with other existing strategies such as spinal implants that boost nerve signaling, which have shown promise in enabling some movement after spinal injury. The presenters close by considering the longer view for life extension and the ethics around body swapping, highlighting the tension between medical possibility and societal values.

Takeaways and outlook

While the retina viability work makes a meaningful step toward eye transplantation and vision restoration, there is still a long road to translating this into a working transplant. The fusogenic spinal cord work shows real potential for restoring movement in cases of severe spinal injury and adds momentum to the field of neural repair, but safety, long term outcomes, and ethical considerations remain central hurdles. The discussion frames these advances as part of the ongoing evolution of transplant medicine, with a cautious eye on how far science can safely push the envelope in pursuit of healing and extended human capabilities.